These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 28903995)

  • 1. ROS1 [corrected].
    Pal P; Khan Z
    J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
    Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M
    Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
    Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
    Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
    J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new target in non-small cell lung cancer: ROS1 fusion gene].
    Cai WJ; Su B
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
    [No Abstract]   [Full Text] [Related]  

  • 7. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.
    Juan O; Popat S
    Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911
    [No Abstract]   [Full Text] [Related]  

  • 8. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathways: ROS1 fusion proteins in cancer.
    Davies KD; Doebele RC
    Clin Cancer Res; 2013 Aug; 19(15):4040-5. PubMed ID: 23719267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
    Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J
    Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
    BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC
    PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of RAS family members confers resistance to ROS1 targeting drugs.
    Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
    Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.
    Pavlakis N; Cooper C; John T; Kao S; Klebe S; Lee CK; Leong T; Millward M; O'Byrne K; Russell PA; Solomon B; Cooper WA; Fox S
    Pathology; 2019 Dec; 51(7):673-680. PubMed ID: 31668406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.